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INCE the pioneering discoveries of nerve growth factor 
(24)  and epidermal growth factor (EGF) ~ (8),  it has 
become clear that polypeptide growth factors play a 
crucial role in the proliferation, survival, and differentiation 
of eukaryotic cells.  Since then,  many new growth factors 
have been discovered; some of them exert their biological 
effects on  specific cell lineages,  while others  have broad 
specificity for many cell types from many tissues (17). EGF, 
because it is the best characterized growth factor, may serve 
as a model system for exploring the molecular mechanisms 
underlying mitogenic stimulation. Moreover, it has become 
clear that specific lesions in the EGF receptor, or abnormal 
expression of growth factors that mediate their effects by ac- 
tivating the EGF receptors, may be associated with certain 
cancers. Therefore, the elucidation of the mechanism of ac- 
tion of EGF will certainly provide important clues to fun- 
damental questions concerning the action of growth factors 
in general and their role in oncogenesis. 
The Structure of the EGF Receptor 
EGF binds to a transmembrane glycoprotein and activates a 
protein tyrosine kinase activity (5). After purification of the 
human  EGF  receptor by  immunoaflinity chromatography 
(45) and its partial sequencing (12),  the complete primary 
structure of the EGF receptor was deduced from nucleotide 
sequence of cDNA clones (38). The following picture of the 
structure of the EGF receptor emerges. The mature receptor 
is composed of 1,186 amino acid residues that are preceded 
at the NH2-terminal end by a signal peptide of 24 hydropho- 
bic amino acids. The signal peptide is cleaved after insertion 
of the nascent receptor into the membrane of the endoplas- 
mic reticulum.  Cotranslationally, the receptor is glycosyl- 
ated  and  transported  through  the  Golgi  apparatus  to  the 
plasma  membrane.  The  mature  receptor is  composed  of 
three major structural elements (Fig.  1). The first is an ex- 
tracellular  EGF-binding  domain  composed of 621  amino 
acid residues, anchored to the plasma membrane by a single 
transmembrane region of 23 hydrophobic amino acids. The 
transmembrane region is followed by a sequence of mostly 
basic residues; a feature common to many membrane pro- 
teins. The cytoplasmic domain of EGF receptor is composed 
of 542 amino acids. It contains a region of ,0300 amino acid 
residues that is homologous to the catalytic domain of the 
protein tyrosine kinase encoded by the src gene family of on- 
cogenes (14). Like the other protein tyrosine kinases,  the 
1. Abbreviations used in this paper:  EGF, epidermal growth factor; LDL, 
low  density lipoprotein. 
catalytic domain of EGF receptor kinase contains a lysine 
(Lys 721) residue (Fig.  1) that is located 15 residues to the 
carboxy-terminal side of a consensus sequence, Gly-X-Gly- 
X-phe-Gly-X-Val.  The lysine residue, together with the con- 
sensus sequence, probably functions as part of the ATP bind- 
ing site (14). 
The binding of EGF to the receptor induces the activation 
of the protein tyrosine kinase, which phosphorylates various 
cellular proteins as well as the EGF receptor itself. In intact 
cells, autophosphorylation occurs mainly on Tyrl173; how- 
ever, at least two additional tyrosine residues located at the 
carboxy-terminal end of EGF receptor are phosphorylated 
when EGF is added to solubilized membranes or to the pure 
receptor (14). It was suggested that the autophosphorylation 
of EGF receptor regulates its capacity to phosphorylate ex- 
ogenous substrates (1). 
A hallmark of the extracellular domain of EGF receptor 
is a  high proportion of cysteine residues clustered in two 
regions,  each  160  residues  long.  The  two  cysteine-rich 
clusters can be aligned to form internal repeats with similar 
spacing between individual residues.  Similar cysteine-rich 
domains were also found in the insulin receptor (13, 37) and 
in  the  HER2/neu  protein,  which probably functions as  a 
membrane receptor for an as yet unknown growth factor (9, 
33). Hence, the cysteine-rich domain of growth factor recep- 
tors probably evolved from a common ancestral gene (28). 
The EGF Receptor and Cell Transformation 
We have shown that the v-erbB oncogene of avian erythro- 
blastosis virus encodes a truncated EGF receptor and pro- 
posed  that  the  v-erbB  protein  induces  transformation by 
functioning as an activated growth factor receptor. (12). The 
v-erbB protein (44) is devoid of most of the extracellular do- 
main of EGF receptor and also of 32 amino acid residues at 
the carboxy-terminal end of the receptor, thus losing the ma- 
jor autophosphorylation site of the native receptor (Fig.  1). 
Nevertheless,  the v-erbB protein,  gp74  wrbB, possesses  in- 
trinsic  protein tyrosine kinase activity towards  exogenous 
substrates  and  also  undergoes  autophosphorylation  (19). 
Chicken erythroblastosis is also caused by avian leukosis vi- 
rus, which transforms these cells by activating the c-erbB/ 
EGF  receptor gene through a  promoter insertion mecha- 
nism. Proviral integration leads to the expression of a trun- 
cated EGF receptor with intrinsic protein tyrosine kinase ac- 
tivity (20). Interestingly, the v-erbB-like proteins expressed 
in  these leukemias  contain the coding information for 34 
amino acids at the COOH terminus that are homologous to 
the  respective sequence of the human  EGF  receptor, but 
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v-erbB protein. The EGF-receptor (right) is depicted as membrane 
protein composed  of an extracellular  EGF-binding  domain  con- 
nected to the cytoplasmic domain by a single transmembrane  re- 
gion.  The cytoplasmic domain contains a protein tyrosine kinase 
with an ATP binding site (consensus Lys 721) and substrate binding 
region. Thr654, which is the major kinase C phosphorylation site, 
is located 10 amino acid residues into the cytoplasmic domain and 
is surrounded by basic residues. The carboxy-terminal tail of EGF 
receptor contains three autophosphorylation sites. The v-erbB pro- 
tein (/eft) is a truncated EGF receptor devoid of most of the extracel- 
lular EGF binding domain and also lacks 32 amino acid residues 
from the carboxy-terminal tail, including the major autophosphory- 
lation site (Tyrl173). 
which are deleted from v-erbB protein (30), thus suggesting 
that the COOH-terminal deletion is not required for erythro- 
blastosis.  Numerous studies suggest that the EGF receptor 
may play a role in oncogenesis through an autocrine mecha- 
nism.  Various  animal  and  human  tumor  cells  produce 
a  growth  factor  called  transforming  growth  factor-alpha 
(alpha-TGF) (36).  This growth  factor is  a  member of the 
EGF gene family. It binds to cells bearing EGF receptor with 
an  affinity  similar  to  that  of  EGF  and  stimulates  their 
proliferation.  Todaro et al.  (36)  suggested that alpha-TGF 
plays a role in oncogenesis by stimulating the growth of cells 
bearing  EGF  receptors  through  an  autocrine  mechanism 
(36). Finally, it was shown that the EGF receptor gene is am- 
plified and rearranged in many human brain tumors of glial 
origin (25).  The resultant overexpression of the EGF recep- 
tor may play a  role  in  the  development or progression of 
these tumors. 
Heterologous Regulation of  EGF 
Receptor Functions 
Binding experiments of ~25I-EGF to EGF receptor on living 
cells reveal two distinct affinity states of EGF receptor (18). 
High affinity sites usually represent 5-10% of the total recep- 
tor population, depending on cell type. This correlates well 
with the optimal receptor occupancy required for the initia- 
tion of DNA synthesis, and, therefore, it was suggested that 
the high affinity receptor plays a role in the mitogenic signal- 
ling process.  The treatment of fibroblasts and  A-431  cells 
with the tumor promoter 12-O-tetradecanoyl phorbol-13-ace- 
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Figure 2.  A model  for heterologous regulation of EGF receptor 
functions (receptor transmodulation).  According to this model the 
binding of growth factor to receptor I (i.e., PDGF to PDGF recep- 
tor or Bombesin  to  Bombesin  receptor)  will activate the  phos- 
phoinositol  pathway by  activating  membrane  phospholipase  C 
(PL-C);  probably through a specific G protein.  This in turn will 
lead to the  generation  of diacyl glycerol  and  immobilization of 
Ca  +: ions necessary for the activation of kinase C. Kinase C phos- 
phorylation of EGF receptor will modulate ligand binding affinity 
and protein tyrosine kinase activity. 
The tumor promoter TPA will short circuit this process by bind- 
ing to and activating kinase C directly. 
tate (TPA) abolished the high affinity state of the EGF recep- 
tor (4, 35) and reduced its protein tyrosine kinase activity (7, 
16). Moreover, the addition of TPA to cells also blocks the 
stimulation of Na+/H+  exchange induced by EGF and by 
other growth factors (40,  41). TPA activates the Ca+2-sensi - 
tive protein kinase C, which in turn phosphorylates the EGF 
receptor on several sites (6). One of these sites is Thr654 of 
the EGF receptor (10, 15); a residue located  10 amino acid 
residues from the membrane in the cytoplasmic domain of 
EGF receptor. Based on these results, it was suggested that 
the phosphorylation of EGF receptor on Thr654  regulates 
the affinity of the extracellular domain towards the ligand and 
the enzymatic activity of the protein tyrosine kinase domain. 
Similar  inhibition  of the  high  affinity state  of the  EGF 
receptor was induced by platelet-derived growth factor and 
bombesin (3,  43).  Both  platelet-derived growth factor and 
bombesin elicit their mitogenic response by binding to their 
specific cell surface receptors.  Moreover, both growth fac- 
tors  stimulate the  phosphoinositol  pathway,  which  in  turn 
may lead to the phosphorylation of EGF receptor by kinase 
C (Fig. 2). Hence, it seems that the binding affinity of EGF 
receptor towards EGF is controlled by heterologous interac- 
tions with other occupied growth factor receptors possibly 
mediated by kinase C (31) that may act as a messenger for such 
receptor transmodulation or receptor cross-talk (Fig.  2).  It 
was  recently  shown  that  in  A-431  cells  EGF  induces  the 
phosphorylation of EGF receptor on Thr654 through the ac- 
tivation of kinase C, thus raising the possibility that in these 
cells kinase C phosphorylation may provide a negative feed- 
back mechanism to control  receptor activity (42). 
Models  for Activation of the EGF Receptor 
An interesting conclusion drawn from the primary structure 
of EGF receptor (38) is that the extracellular ligand binding 
domain is connected to the cytoplasmic kinase region by a 
single  transmembrane  region.  This  is  in  contrast  to other 
transmembrane  proteins  that  are  also  involved  in  signal 
transduction across the plasma membrane and that usually 
traverse the lipid bilayer more than once. Two distinct mech- 
anisms can be reasoned for the transmembrane signalling of 
The Journal  of Cell  Biology,  Volume  103,  1986  2068 membrane proteins with a single transmembrane region such 
as the EGF receptor (46-48). In an intramolecular model a 
vertical dislocation of the membrane hydrophobic stretch of 
EGF receptor is required for the transfer of a conformational 
change from the ligand binding domain to the cytoplasmic 
kinase region.  However, the juxtamembranal  sequence of 
EGF receptor contains charged amino acids at both faces of 
the plasma membrane, which may impose a high energy bar- 
rier for a putative vertical conformational change from the 
extracellular domain to the cytoplasmic region (28, 38). 
An alternative mechanism involves an intermolecular al- 
losteric process in which ligand-induced receptor oligomeri- 
zation leads to the activation of the protein tyrosine kinase 
domain by subunit interaction between neighboring cytoplas- 
mic domains, thus bypassing the requirement for a confor- 
mational change to propagate through the transmembrane re- 
gion  (Fig.  3).  Recent  results  indicate  that  EGF-induced 
activation of its receptor kinase may involve an intermolecu- 
lar step (46-48). However, once the receptor is activated, au- 
tophosphorylation seems to proceed by an intramolecular 
process (39,  47).  It was  shown that EGF-induced receptor 
self-phosphorylation has a parabolic dependence on the con- 
centration of EGF receptor and that cross-linking of EGF 
receptor by antibodies or lectins  stimulates  receptor self- 
phosphorylation. Moreover, immobilization of EGF recep- 
tor on various solid matrices prevents EGF from activating 
the kinase function (46-48). It was also shown that in native 
gels, EGF receptor migrates in two forms: a fast-migrating 
form and an EGF-induced slow-migrating form. Based on 
various control and calibration experiments (48) it was con- 
cluded that the low form represents the monomeric 170-kD 
EGF receptor and the high form represents an EGF receptor 
dimer.  The binding  of EGF causes  a  rapid,  temperature- 
sensitive dimerization of EGF receptors. Receptor dimeriza- 
tion is fully reversible and involves saturable, noncovalent 
interactins that are stable at neutral pH and in nonionic deter- 
gents. 
Internalization of  EGF Receptor 
Like many other  serum  proteins,  EGF  is  internalized by 
receptor-mediated  endocytosis.  Unlike  the  low  density 
lipoprotein (LDL) receptor, which is preclustered in coated 
pits (2), EGF receptors are randomly dispersed on the cell 
surface (reviewed in 34). The occupied EGF receptors clus- 
ter in coated pits, and, after internalization, both EGF and 
its receptor are degraded by lysosomal enzymes. Hence, in 
contrast to the recycling of LDL receptor that is ligand-inde- 
pendent, EGF appears to facilitate the entry of its receptor 
into coated pits.  The selectivity of this process may imply 
recognition signals  that are associated with receptors that 
will facilitate their entry to and association with coated pits. 
Since clathrin and other proteins that are associated with 
coated pits are located in the cytoplasmic side of the plasma 
membrane, it is possible that the putative recognition sites 
of receptors reside in their cytoplasmic domains.  Indeed, 
mutations in the cytoplasmic domain of LDL receptor impair 
its ability to cluster in coated pits and abolish receptor en- 
docytosis (2, 22, 23). However, EGF receptor does not share 
sequence similarity with  the LDL receptor or with other 
receptors that enter the cells via the coated pits pathway. 
MONOMER  OLIGOMER 
LOW  LIGAND AFFINITY 
LOW  KINASE ACTIVITY 
HIGH  LIGAND AFFINITY 
STIMULATED KINASE ACTIVITY 
Figure 3. An allosteric oligomerization model for the activation of 
the EGF receptor kinase by EGF. EGF receptor is depicted as a 
biglobular transmembrane molecule as shown in Fig.  I. It is pro- 
posed that monomeric receptors exist in equilibrium with receptor 
oligomers. It is postulated that monomeric receptors possess low 
ligand affinity and reduced kinase activity and oligomeric receptors 
have high binding affinity and stimulated kinase activity. Hence, 
EGF binding will drive the aggregation process and thus stimulate 
the protein tyrosine kinase activity. 
Hence, it is possible that the clustering in coated pits is medi- 
ated by chemical modifications added posttranslationally to 
the receptor protein by some other as yet uncharacterized 
processes. 
It is clear from the results presented so far that EGF recep- 
tor is a multifunctional allosteric protein with several regula- 
tory sites.  These regulatory sites modulate various receptor 
functions such as: ligand affinity, receptor clustering and en- 
docytosis, protein tyrosine kinase activity, and the state of 
receptor phosphorylation. An approach that affords the anal- 
ysis of the various structural domains of the EGF receptor 
is the use of site-directed in vitro mutagenesis of EGF recep- 
tor cDNA combined with transfection experiments into het- 
erologous animal cells. This approach was used to generate 
various EGF receptor mutants that were used for addressing 
questions of mechanism concerning the action and regula- 
tion of EGF receptor. Three types of EGF receptor mutants 
were already described;  deletion mutants  (27, 29,  Reidel, 
H.,  J.  Lee,  T.  J.  Dull,  R.  M.  Kris,  M.  D.  Waterfield, 
J.  Schlessinger, and A.  Ullrich,  manuscript submitted for 
publication),  insertional  mutants  (32),  and  point mutants 
(26).2 
Properties of  Deletion Mutants of  EGF Receptor 
DNA sequences encoding the human EGF receptor and vari- 
ous  EGF  receptor deletion mutants  were transfected into 
Chinese hamster ovary cells (CHO) that were devoid of EGF 
receptor. A functional EGF receptor was expressed in these 
cells. Like the native receptor, the EGF receptor expressed 
in the CHO cells has an apparent molecular mass of 170 kD. 
Moreover, it possesses an intrinsic protein tyrosine kinase 
activity that is stimulated by EGF leading to increased recep- 
tor self-phosphorylation and to the phosphorylation of exog- 
enous substrates.  The reconstituted EGF receptor exhibits 
typical two-affinity states toward EGE Approximately 10% 
of the receptors exhibit a Kd of ~3  ×  10  -1° M  (high affinity 
receptors) while the rest of the receptors have a Kd of ~2  × 
10  -9 M (low affinity receptors). It appears that both affinity 
2. Livneh, E., R. Prywes, T. Dull, A. Ullrich, and J. Schlessinger, manu- 
script submitted for publication. 
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the 170-kD EGF receptor expressed on the cell surface (Fig. 
3) has the capacity to acquire two affinity states toward EGF 
(Fig. 4). This may be mediated by different oligomerization 
states of EGF receptor on the cell surface or by interactions 
with other unknown membrane or cytoskeletal molecules. 
The reconstituted EGF receptor undergoes efficient EGF- 
induced endocytosis. Moreover, EGF stimulates  the CHO 
cells expressing the EGF receptor to undergo DNA synthe- 
sis. Deletion of 63 amino acids from the COOH-terminal tail 
of EGF receptor, which removes two autophosphorylation 
sites,  abolishes the high affinity state of the EGF receptor 
(Fig.  4).  Nevertheless, this receptor mutant is able to un- 
dergo  endocytosis  and  to  respond  mitogenically  to  the 
growth factor. Hence, the high affinity state of EGF receptor 
is not required for efficient endocytosis and DNA synthesis. 
Further deletions from the cytoplasmic domain give rise to 
low affinity endocytosis-defective receptor mutants. One of 
these mutants possesses 98 cytoplasmic amino acids and is 
devoid of most of the protein tyrosine kinase domain (Fig. 
4). A larger deletion from the carboxy-terminal tail yields a 
receptor mutant with a short cytoplasmic tail of nine amino 
acids without Thr654, which is the major kinase C  phos- 
phorylation site (Fig. 4). Finally, deletion of the transmem- 
brane region of the human  EGF  receptor yields an  EGF 
receptor ligand  binding domain that is  secreted from the 
CHO cells (29). 
Reidel  and  co-workers (Reidel,  H.,  J.  Lee,  T.  J.  Dull, 
R. M. Kris, M. D. Waterfield, J. Schlessinger, and A. Ull- 
rich, manuscript submitted for publication) generated a hu- 
man counterpart of the v-erbB oncogene; namely, a cDNA 
construct encoding a double-truncated EGF receptor (Fig. 
4). It was shown that this construct is able to transform Ratl 
cells, thus indicating that truncation of most of the extracel- 
lular domain and deletion of 32 residues from the carboxy- 
terminal end converts the EGF receptor into a transforming 
protein. 
Insertional Mutants of the EGF Receptor 
A murine retrovirus vector was used to express the human 
EGF receptor cDNA and two insertional mutants of the EGF 
receptor in mouse 3T3 cells (32). Synthetic SalI linkers en- 
coding four amino acid residues were inserted in the kinase 
domain of EGF receptor to explore the role of this region on 
other known biological properties of the EGF receptor (32). 
A  four amino acid insertion after residue 888 of the EGF 
receptor  abolished  protein  tyrosine  kinase  activity,  high 
affinity binding, internalization, and mitogenic responsive- 
ness (Fig. 4). Another four amino mutation at residue 708 
abolished  the  protein  tyrosine kinase  activity  of the  im- 
munoprecipitated receptor (Fig. 4). However, this receptor 
mutant exhibited both the high and low affinity binding affini- 
ties  towards  EGF  and  was  able  to  internalize  nESI-EGF 
efficiently into these cells.  Surprisingly,  EGF was  able to 
stimulate DNA synthesis in these cells as efficiently as in 
NIH-3T3 cells expressing the wild type receptor construct 
(32). The properties of this mutant may suggest that the ki- 
nase activity is not required for internalization and mitogene- 
sis.  However, an alternative and more plausible interpreta- 
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Figure 4. A summary of the properties of EGF receptor mutants. Details concerning the properties of these EGF receptor mutants are 
described in the text. The symbols used for the various established cell lines are as follows: mouse NIH-3T3, N; chinese hamster ovary 
cells (CHO), C; mouse L cells, L; and Ratl cells, R. EGF induced two to threefold thymidine incorporation into the CHO cells expressing 
the human EGF receptor and 5-10-fold stimulation of thymidine incorporation into the NIH-3T3 cells expressing the EGF receptor. It is 
noteworthy that the EGF receptor insertion mutant at residue 708 does not possess protein tyrosine kinase activity in our in vitro assays 
(Prywes et al., 1986). However, phosphorylation experiments in living cells indicate that under these conditions EGF is able to stimulate 
receptor autophosphorylation (Livneh, E., and J. Schlessinger, unpublished data). For further details see text. 
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renders the immunoprecipitated kinase unstable and there- 
fore defective in the in vitro assays for autophosphorylation 
and  exogenous  substrate  phosphorylation,  while  in  intact 
cells, this receptor mutant may possess kinase activity capa- 
ble of phosphorylating the physiologically  important sub- 
strates.  Indeed, we have recently shown (Livneh, E., and J. 
Schlessinger, unpublished data) that EGF is able to stimulate 
the  autophosphorylation of this  receptor  mutant in  living 
cells. Hence, more studies with new receptor mutants are re- 
quired for establishing the role of the protein tyrosine kinase 
function in mediating the biological responses of EGE 
Point Mutations of the EGF Receptor 
As shown earlier, Thr654 is the major kinase C phosphoryla- 
tion site of EGF receptor. To probe the function of this amino 
acid residue, Thr654 was replaced either by an alanine resi- 
due  (26)  or by  a  tyrosine  2 residue  utilizing in vitro  site- 
directed mutagenesis.  The Ala654 mutant of EGF receptor 
was expressed in mouse L cells (devoid of endogenous EGF 
receptor) and in RAT1  cells that possess endogenous EGF 
receptor. The properties of these mutants are summarized in 
Fig. 4. It appears that the Ala654 mutant of EGF receptor 
expressed in the heterologous cells did not internalize in re- 
sponse to TPA,  although EGF was still able to induce en- 
docytosis and degradation of the mutated receptor.  On the 
basis of these results it was proposed that two independent 
mechanisms,  one using Thr654 phosphorylation and a sec- 
ond mechanism that is EGF-dependent, play a role in the in- 
ternalization of EGF  receptor (26).  The second mutant of 
EGF receptor contained a tyrosine residue instead of Thr654 
(Fig.  4).  In this receptor mutant Thr654 is replaced by an 
amino acid that is a potential phosphate acceptor site but can- 
not be phosphorylated by kinase C.  The Tyr654 mutant of 
EGF  receptor was  expressed  in NIH-3T3  (<1,000 endoge- 
nous EGF receptors/cell) and in CHO cells that are devoid 
of EGF receptor.  Like the wild type receptor expressed on 
the surface of the NIH-3T3 cells, the Tyr654 receptor mutant 
exhibited both the high and the low  affinity  states  toward 
EGE  The addition of TPA abolished the high affinity state 
of both the wild type and the Tyr654 receptor mutant in a 
similar  manner. 2 Interestingly,  the  CHO  cells  expressing 
the  Tyr654  receptor  mutant  exhibited  a  single  binding 
affinity toward EGF (Fig. 4). 
The mitogenic capacity of EGF can either be enhanced (11) 
or inhibited (21) by TPA, depending on cell type. It appears 
that in  the  NIH-3T3  cells  expressing  the wild  type  EGF 
receptor,  TPA  blocks  the mitogenic capacity  of EGE 2 In- 
terestingly, the inhibition mediated by TPA in cells express- 
ing the wild type receptor does not occur in cells expressing 
the Tyr654 EGF receptor mutant. Namely,  EGF is able to 
stimulate DNA synthesis in these cells even in the presence 
of TPA, which inhibits the mitogenic capacity of EGF in the 
3T3 cells expressing the wild type receptor. 2 On the basis of 
these results, we propose that the phosphorylation of Thr654 
by kinase C may provide a negative control mechanism for 
EGF-induced mitogenesis. 2 
In  summary,  the EGF  receptor  represents  an allosteric 
protein composed of several regulatory domains with differ- 
ent functions. Detailed structure/function analysis using in 
vitro site-directed mutagenesis combined with expression of 
receptor mutants in heterologous cells will resolve the mech- 
anisms underlying the regulation of the affinity state of the 
EGF receptor, activation of the protein tyrosine kinase, en- 
docytosis, and, eventually, the structural elements that con- 
trol  DNA  synthesis  and  oncogenesis.  Since  EGF  and  its 
receptor  are  also  a  good  model  system  for  other  growth 
promoting factors, these studies will provide important clues 
for understanding the mechanisms underlying normal growth 
control and oncogenesis in general. 
I  would  like to acknowledge  fruitful  discussions  with E.  Livneh,  A.  M. 
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